[go: up one dir, main page]

MX2023011909A - Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso. - Google Patents

Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.

Info

Publication number
MX2023011909A
MX2023011909A MX2023011909A MX2023011909A MX2023011909A MX 2023011909 A MX2023011909 A MX 2023011909A MX 2023011909 A MX2023011909 A MX 2023011909A MX 2023011909 A MX2023011909 A MX 2023011909A MX 2023011909 A MX2023011909 A MX 2023011909A
Authority
MX
Mexico
Prior art keywords
rnai agents
rage
compositions
receptor
products
Prior art date
Application number
MX2023011909A
Other languages
English (en)
Inventor
Erik W Bush
Anthony Nicholas
Casi M Schienebeck
David Itiro Kasahara
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MX2023011909A publication Critical patent/MX2023011909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen agentes de RNAi, composiciones que incluyen agentes de RNAi y métodos para la inhibición de un gen receptor de productos finales de glicación avanzada (AGER o RAGE). Los agentes de RNAi de RAGE y los conjugados de agentes de RNAi divulgados en el presente documento inhiben la expresión de un gen AGER. También se describen composiciones farmacéuticas que incluyen uno o más agentes de RNAi de RAGE, opcionalmente con uno o más terapéuticos adicionales. La administración de los agentes de RNAi de RAGE descritos a células pulmonares, in vivo, proporciona la inhibición de la expresión del gen AGER y una reducción de la actividad RAGE de membrana, que puede proporcionar un beneficio terapéutico a los sujetos, incluidos sujetos humanos, para el tratamiento de diversas enfermedades, incluidas las enfermedades de inflamación pulmonar tales como asma grave.
MX2023011909A 2021-04-08 2022-04-07 Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso. MX2023011909A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163172301P 2021-04-08 2021-04-08
US202263322603P 2022-03-22 2022-03-22
PCT/US2022/023813 WO2022216920A1 (en) 2021-04-08 2022-04-07 Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use

Publications (1)

Publication Number Publication Date
MX2023011909A true MX2023011909A (es) 2023-10-18

Family

ID=83545747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011909A MX2023011909A (es) 2021-04-08 2022-04-07 Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.

Country Status (15)

Country Link
US (1) US12486502B2 (es)
EP (1) EP4319765A1 (es)
JP (1) JP2024516096A (es)
KR (1) KR20230167082A (es)
AU (1) AU2022254705A1 (es)
BR (1) BR112023020626A2 (es)
CA (1) CA3213968A1 (es)
CL (1) CL2023002985A1 (es)
CO (1) CO2023013243A2 (es)
IL (1) IL307421A (es)
MX (1) MX2023011909A (es)
PE (1) PE20240766A1 (es)
PH (1) PH12023552779A1 (es)
TW (1) TW202304474A (es)
WO (1) WO2022216920A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023447308A1 (en) * 2023-05-05 2025-10-16 RAGE Biotech Pty Ltd Administration of oligonucleotides
TW202509217A (zh) * 2023-08-24 2025-03-01 大陸商上海拓界生物醫藥科技有限公司 靶向ＲＡＧＥ的ＲＮＡｉ劑及其醫藥用途
WO2025067322A1 (zh) * 2023-09-27 2025-04-03 长春金赛药业有限责任公司 一种新的siRNA、包含其的组合物及用途
WO2025067423A1 (zh) * 2023-09-27 2025-04-03 上海拓界生物医药科技有限公司 含三氮唑基化合物、制备方法及用途
CN120309684A (zh) * 2024-01-15 2025-07-15 武汉人福创新药物研发中心有限公司 靶向化合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
DE50007899D1 (de) 1999-02-20 2004-10-28 Merck Patent Gmbh Beta-alaninderivate
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
DE19929410A1 (de) 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US9994853B2 (en) * 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
MXPA05001758A (es) 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US20080213249A1 (en) 2006-07-07 2008-09-04 The Scripps Research Insitute Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting
CN103524619B (zh) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009069727A1 (ja) 2007-11-28 2009-06-04 Fujifilm Corporation 生体高分子およびポリペプチドの化学修飾方法
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
CN102869774B (zh) 2010-02-24 2018-02-09 箭头研究公司 用于靶向递送siRNA的组合物
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
BR112014004585A2 (pt) 2011-08-26 2017-06-13 Arrowhead Res Corp polímeros de poli(éster vinílico) para liberação de ácido nucleico in vivo
EP2814509B1 (en) 2012-02-17 2018-05-16 Seattle Genetics, Inc. Antibodies to integrin v 6 and use of same to treat cancer
EP2650013A1 (en) 2012-04-10 2013-10-16 Deutsches Krebsforschungszentrum Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
AU2012377385A1 (en) 2012-04-18 2014-01-23 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
JP2014029990A (ja) 2012-06-29 2014-02-13 Sharp Corp 窒化物半導体装置の電極構造およびその製造方法並びに窒化物半導体電界効果トランジスタ
US20160040125A1 (en) 2013-03-26 2016-02-11 Biocant - Centro De Inovação Em Biotecnologia A human blood-brain barrier model derived from stem cells
JP2015040181A (ja) 2013-08-20 2015-03-02 学校法人立命館 カロテノイドの新規用途、並びにバリア機能改善薬のスクリーニング方法
AU2014312211A1 (en) 2013-08-28 2016-03-10 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
ES2930029T3 (es) 2014-04-15 2022-12-05 Univ California Péptidos de unión a integrina pegilados biterminales y métodos para su uso
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
EP3270903B1 (en) 2015-03-17 2020-05-06 Arrowhead Pharmaceuticals, Inc. Disulfide-containing alkyne linking agents
US9976141B2 (en) 2015-05-29 2018-05-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of Hif2alpha
EP3464313A4 (en) 2016-06-06 2020-02-26 Arrowhead Pharmaceuticals, Inc. MODIFIED NUCLEOTIDES 5 '-CYCLO-PHOSPHONATE
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
IL305158A (en) 2016-11-01 2023-10-01 Arrowhead Pharmaceuticals Inc Ligands of alpha-V beta-6 integrin and their uses
EP3703700A4 (en) 2017-11-01 2021-08-04 Arrowhead Pharmaceuticals, Inc. INTEGRIN LIGANDS AND USES OF THESE LATEST
CA3089276A1 (en) 2018-02-17 2019-08-22 Arrowhead Pharmaceuticals, Inc. Trialkyne linking agents and methods of use
US20220265864A1 (en) 2019-08-15 2022-08-25 Lifesplice Pharma Llc Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use

Also Published As

Publication number Publication date
TW202304474A (zh) 2023-02-01
AU2022254705A1 (en) 2023-10-05
BR112023020626A2 (pt) 2023-12-19
KR20230167082A (ko) 2023-12-07
WO2022216920A1 (en) 2022-10-13
US12486502B2 (en) 2025-12-02
PE20240766A1 (es) 2024-04-17
CA3213968A1 (en) 2022-10-13
JP2024516096A (ja) 2024-04-12
EP4319765A1 (en) 2024-02-14
IL307421A (en) 2023-12-01
CL2023002985A1 (es) 2024-04-19
PH12023552779A1 (en) 2024-04-15
CO2023013243A2 (es) 2023-10-30
US20220396791A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
MX2023011909A (es) Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.
CA3189065A1 (en) Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
Nygaard et al. Emerging treatment options in atopic dermatitis: topical therapies
Miyahara et al. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma
Yamawaki et al. Nrf2 activator for the treatment of kidney diseases
McCarthy et al. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP4124346A3 (en) Compositions and methods for treating diseases
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
AR079057A1 (es) Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
Jin et al. Fragmentation level determines mitochondrial damage response and subsequently the fate of cancer cells exposed to carbon ions
Hu et al. Isovitexin depresses osteoarthritis progression via the Nrf2/NF-κB pathway: an in vitro study
CL2023003505A1 (es) Agentes de rnai para inhibir la expresión de mucina 5ac (muc5ac), composiciones de los mismos y métodos de uso.
MX2024004912A (es) Agentes de arni para inhibir la expresion de la metaloproteinasa de matriz 7 (mmp7), composiciones de los mismos y metodos de uso.
AU2011270096B2 (en) Agent for suppressing the formation of abnormal skin cells caused by exposure to light
WO2023150622A3 (en) Rnai agents for inhibiting expression of coronavirus (cov) viral genomes, compositions thereof, and methods of use
Flinn et al. Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.
WO2023183814A3 (en) Subcutaneous delivery of rnai agents for inhibiting expression of receptor for advanced glycation end-products (rage)
WO2024173520A3 (en) Rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereof, and methods of use
Hu et al. Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells
WO2023245060A3 (en) Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
NZ588470A (en) Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases